Publication | Closed Access
Tumor-Acidity and Bioorthogonal Chemistry-Mediated On-Site Size Transformation Clustered Nanosystem to Overcome Hypoxic Resistance and Enhance Chemoimmunotherapy
77
Citations
45
References
2022
Year
NanotherapeuticsEngineeringNitric OxideRapid Response RateImmunotherapeuticsBiomedical EngineeringTumor BiologyNanomedicineTherapeutic NanomaterialsOvercome Hypoxic ResistanceTumor ImmunityEnhance ChemoimmunotherapySlow Response RateRadiation OncologyTumor TargetingPharmacologyTumor MicroenvironmentBiomolecular EngineeringDrug TargetingPolymer-drug ConjugateDrug Delivery SystemsNano-drug DeliveryMedicine
Hypoxia, a common feature of most solid tumors, causes severe tumor resistance to chemotherapy and immunotherapy. Herein, a tumor-acidity and bioorthogonal chemistry-mediated on-site size transformation clustered nanosystem is designed to overcome hypoxic resistance and enhance chemoimmunotherapy. The nanosystem utilized the tumor-acidity responsive group poly(2-azepane ethyl methacrylate) with a rapid response rate and highly efficient bioorthogonal click chemistry to form large-sized aggregates in tumor tissue to enhance accumulation and retention. Subsequently, another tumor-acidity responsive group of the maleic acid amide with a slow response rate was cleaved allowing the aggregates to slowly dissociate into ultrasmall nanoparticles with better tumor penetration ability for the delivery of doxorubicin (DOX) and nitric oxide (NO) to a hypoxic tumor tissue. NO can reverse a hypoxia-induced DOX resistance and boost the antitumor immune response through a reprogrammed tumor immune microenvironment. This tumor-acidity and bioorthogonal chemistry-mediated on-site size transformation clustered nanosystem not only helps to counteract a hypoxia-induced chemoresistance and enhance antitumor immune responses but also provides a general drug delivery strategy for enhanced tumor accumulation and penetration.
| Year | Citations | |
|---|---|---|
Page 1
Page 1